FSD Pharma Inc. (HUGE): Price and Financial Metrics
GET POWR RATINGS... FREE!
HUGE Stock Price Chart Interactive Chart >
HUGE Price/Volume Stats
| Current price | $1.62 | 52-week high | $1.88 |
| Prev. close | $1.59 | 52-week low | $0.62 |
| Day low | $1.58 | Volume | 57,000 |
| Day high | $1.65 | Avg. volume | 166,672 |
| 50-day MA | $1.40 | Dividend yield | N/A |
| 200-day MA | $1.00 | Market Cap | 61.73M |
FSD Pharma Inc. (HUGE) Company Bio
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.
Latest HUGE News From Around the Web
Below are the latest news stories about FSD PHARMA INC that investors may wish to consider to help them evaluate HUGE as an investment opportunity.
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive DisorderTORONTO, March 22, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that its Australian entity, FSD Pharma Australia Pty Ltd. received the certificate of approval from The Alfred Ethics Committee in Australia to proceed with a Phase 1 clinical |
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its StockTORONTO, March 14, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that it has renewed the service agreement with ShareIntel-Shareholder Intelligence Services, LLC (www.shareintel.com) ("ShareIntel") to assist in ongoing investigations related |
InvestmentPitch Media Video Discusses FSD Pharma’s Addition of Kevin Harrington, Author, “Shark Tank” Original, and Infomercial Pioneer to its Advisory BoardVANCOUVER, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced the addition of iconic entrepreneur Kevin Harrington to its Advisory Board. Kevin Harrington, inventor of the modern infomercial format, pioneer of the “As Seen on TV” brand, and |
Original "Shark" and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory BoardTORONTO, February 28, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that iconic entrepreneur Kevin Harrington has joined the Company’s Advisory Board. |
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 ForumTORONTO, February 21, 2023--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced upcoming participation in Americas Committee for Treatment and Research in Multiple Sclerosis ("ACTRIMS") 2023 Forum being held Feb. 23-25, 2023, in San Diego, California at |
HUGE Price Returns
| 1-mo | -7.95% |
| 3-mo | 105.48% |
| 6-mo | 96.36% |
| 1-year | 80.00% |
| 3-year | -53.71% |
| 5-year | N/A |
| YTD | 105.48% |
| 2022 | -22.71% |
| 2021 | -34.62% |
| 2020 | -71.26% |
| 2019 | -87.37% |
| 2018 | 755.60% |
Loading social stream, please wait...